Clinical trial
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and…
NCT00463203 · Rigshospitalet, Denmark, Other · Completed
Key facts
| NCT number | NCT00463203 |
|---|---|
| Title | Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain Neoplasms, Glioma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Irinotecan |
| Enrollment | 54 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Apr 20, 2007 |
| Last update posted | Jun 29, 2011 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: